Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in ...

Investors are closely monitoring ADCT, a company with $70.72M in revenue and a market cap of $156.64M, as it navigates through the pressures affecting the biotechnology sector. The company's ...

ADC Therapeutics (NYSE:ADCT – Get Free Report) is expected to be announcing its earnings results before the market opens on ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

ADC THERAPEUTICS SA -REDH ($ADCT) is expected to release its quarterly earnings data on Thursday, March 13th after market close, per Finnhub. Analysts are expecting ...

Adc Therapeutics SA (ADCT), a biotechnology firm specializing in the development of antibody-drug conjugates for cancer treatment, has seen its stock price touch a 52-week low, reaching $1.66.